BACKGROUND:Panic disorder (PD) and generalized anxiety disorder (GAD) are often unrecognized by primary care physicians (PCPs). The Primary Care Evaluation of Mental Disorders (PRIME-MD) has been used as a case-finding instrument for depression. Yet, little is known on its usefulness as a case-finding tool for anxiety disorders within the context of a clinical trial. OBJECTIVE: To examine the: (1) completion rate of the PRIME-MD by patients approached to enroll in a treatment study for PD and GAD; (2) distribution of anxiety diagnoses generated; (3) severity of PD and GAD episodes thus identified; and (4) level of PCPs' agreement with these diagnoses. DESIGN: Cross-sectional interview. PATIENTS: Individuals aged 18 to 64 who presented for care at 4 primary care practices. MEASUREMENTS: The PRIME-MD, Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A), and the Panic Disorder Severity Scale (PDSS). RESULTS: Of the 6,700 patients who completed the PRIME-MD Patient Questionnaire (PQ), 2,926 (44%) screened positive for an anxiety disorder, and 1,216 (42%) met preliminary study eligibility and consented to the PRIME-MD Anxiety Module. Of these, 619 (51%) had either GAD (308), PD (94), or both (217) disorders. Later, 329 completed a telephone interview. Of these, 59% with GAD and 68% with PD reported moderate or greater levels of anxiety symptoms on the SIGH-A and PDSS, respectively, and PCPs agreed with the PRIME-MD diagnosis for 98% of these patients. CONCLUSIONS: The PRIME-MD can efficiently screen patients for PD and GAD. Although patients thus identified endorse a wide range of anxiety symptoms, PCPs often agree with the diagnosis.
RCT Entities:
BACKGROUND:Panic disorder (PD) and generalized anxiety disorder (GAD) are often unrecognized by primary care physicians (PCPs). The Primary Care Evaluation of Mental Disorders (PRIME-MD) has been used as a case-finding instrument for depression. Yet, little is known on its usefulness as a case-finding tool for anxiety disorders within the context of a clinical trial. OBJECTIVE: To examine the: (1) completion rate of the PRIME-MD by patients approached to enroll in a treatment study for PD and GAD; (2) distribution of anxiety diagnoses generated; (3) severity of PD and GAD episodes thus identified; and (4) level of PCPs' agreement with these diagnoses. DESIGN: Cross-sectional interview. PATIENTS: Individuals aged 18 to 64 who presented for care at 4 primary care practices. MEASUREMENTS: The PRIME-MD, Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A), and the Panic Disorder Severity Scale (PDSS). RESULTS: Of the 6,700 patients who completed the PRIME-MD Patient Questionnaire (PQ), 2,926 (44%) screened positive for an anxiety disorder, and 1,216 (42%) met preliminary study eligibility and consented to the PRIME-MD Anxiety Module. Of these, 619 (51%) had either GAD (308), PD (94), or both (217) disorders. Later, 329 completed a telephone interview. Of these, 59% with GAD and 68% with PD reported moderate or greater levels of anxiety symptoms on the SIGH-A and PDSS, respectively, and PCPs agreed with the PRIME-MD diagnosis for 98% of these patients. CONCLUSIONS: The PRIME-MD can efficiently screen patients for PD and GAD. Although patients thus identified endorse a wide range of anxiety symptoms, PCPs often agree with the diagnosis.
Authors: Bruce L Rollman; Bea Herbeck Belnap; Charles F Reynolds; Herbert C Schulberg; M Katherine Shear Journal: Gen Hosp Psychiatry Date: 2003 Mar-Apr Impact factor: 3.238
Authors: M K Shear; T A Brown; D H Barlow; R Money; D E Sholomskas; S W Woods; J M Gorman; L A Papp Journal: Am J Psychiatry Date: 1997-11 Impact factor: 18.112
Authors: A C Leon; M Olfson; M M Weissman; L Portera; B H Fireman; R S Blacklow; C Hoven; W E Broadhead Journal: J Gen Intern Med Date: 1996-07 Impact factor: 5.128
Authors: Natalia E Morone; Bea Herbeck Belnap; Fanyin He; Sati Mazumdar; Debra K Weiner; Bruce L Rollman Journal: J Gen Intern Med Date: 2012-08-10 Impact factor: 5.128
Authors: Helen Christensen; Adam J Guastella; Andrew J Mackinnon; Kathleen M Griffiths; Claire Eagleson; Philip J Batterham; Kanupriya Kalia; Justin Kenardy; Kylie Bennett; Ian B Hickie Journal: Trials Date: 2010-04-30 Impact factor: 2.279
Authors: Sarah A Webb; Gretchen Diefenbach; Paula Wagener; Diane M Novy; Mark Kunik; Howard M Rhoades; Melinda A Stanley Journal: J Geriatr Psychiatry Neurol Date: 2008-12 Impact factor: 2.680
Authors: Christopher J Miller; Andrew Grogan-Kaylor; Brian E Perron; Amy M Kilbourne; Emily Woltmann; Mark S Bauer Journal: Med Care Date: 2013-10 Impact factor: 2.983
Authors: Jessica Calleo; Melinda A Stanley; Anthony Greisinger; Oscar Wehmanen; Michael Johnson; Diane Novy; Nancy Wilson; Mark Kunik Journal: J Clin Psychol Med Settings Date: 2009-01-18